- Federal judge in Maryland denied
Akebia ’s request for an order that prevents the Centers for Medicare & Medicaid Services from eliminating coverage under Medicare Part D for Auryxia while a lawsuit is pending. - Akebia was seeking the preliminary injunction as it pursues a lawsuit against the agency
- Drug is used to treat iron deficiency anemia in patients with chronic kidney disease
- CMS said it would only cover payment of Auryxia for its first indication, hyperphosphatemia in patients who receive dialysis
- Akebia hasn’t shown a likelihood of winning its case or that it will suffer irreparable harm, District Court Judge ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.